The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).
 
Rahul K Das
Employment - GNS Healthcare
Leadership - New England Biolabs (I)
 
Leon Furchtgott
Employment - GNS Healthcare
 
Jeffrey A. Meyerhardt
Honoraria - Chugai Pharma; Ignyta
Consulting or Advisory Role - Genentech/Roche
 
Andrew B. Nixon
Consulting or Advisory Role - Pfizer
Research Funding - Acceleron Pharma; Amgen; Genentech/Roche; Incyte; Leadiant Biosciences; medpacto; Novartis; Seagen; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent (Inst); Patent Pending (Inst)
Travel, Accommodations, Expenses - TRACON Pharma
 
Federico Innocenti
Patents, Royalties, Other Intellectual Property - Royalties from the Mayo Foundation on the UGT1A1 testing
 
Daniel Cunha
Employment - GNS Healthcare
 
Kelly Rich
Employment - GNS Healthcare
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Merck Serono; Roche
Consulting or Advisory Role - Bayer; Merck Serono; Pfizer; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche
 
Donna Niedzwiecki
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); Amgen; Antengene (I); Aptus Clinical; ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); CytomX Therapeutics; Daiichi Sankyo (I); Debiopharm Group (I); Delcath Systems (I); Eisai (I); Exelixis (I); Gilead Sciences; Halozyme (I); Inovio Pharmaceuticals; Ipsen (I); Merck (I); Merrimack; Onxeo (I); PCI Biotech (I); Sanofi; Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); Yakult Pharmaceutical (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst); Roche (Inst)
 
Fang-Shu Ou
No Relationships to Disclose
 
Jeanne Latourelle
Employment - GNS Healthcare
 
Diane Wuest
Employment - GNS Healthcare
 
Boris Hayete
Employment - GNS Healthcare
 
Iya Khalil
Employment - GNS Healthcare
 
Alan P. Venook
Consulting or Advisory Role - Bayer; Halozyme; Merrimack; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Serono (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Genentech; Halozyme; Roche; Taiho Pharmaceutical